In these studies, PSMA PET/CT was performed for staging and restaging of RCC, evaluation of primary RCC lesions, or other purposes (e.g., prostate cancer restaging) with incidental detection of RCC metastases. This evidence concerns the gene FOLH1 and renal cell carcinoma.